Return to Listing

12 result(s) for Phase I Clinical Trials

PI Name Protocol # Title
Christopher Ryan STUDY00020946 A Multicenter Phase 1/2, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients with Advanced Tumors and Tenosynovial Giant Cell Tumor
Shivaani Kummar STUDY00021194 A phase 1 study of SGN-CD228A in select advanced solid tumors
Shivaani Kummar STUDY00021766 A Phase I/Ib Study to Evaluate the Safety, Tolerability, Biological and Clinical Activities of GEN-001 in Combination with Avelumab in Patients with Advanced Solid Tumors Who Have Progressed during or after Treatment with Anti-PD-(L)1 therapy
Shivaani Kummar STUDY00021819 A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors
Shivaani Kummar STUDY00022082 A Phase 1b, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Camidanlumab Tesirine (ADCT-301) as Monotherapy or in Combination in Patients With Selected Advanced Solid Tumors
Shivaani Kummar STUDY00022223 A Phase 1a/1b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PY159 as a Single Agent and In Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
Shivaani Kummar STUDY00022760 A Phase 2, Multi-Arm Study of Magrolimab in Patients with Solid Tumors
Shivaani Kummar STUDY00022863 A Phase 1a/1b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PY314 as a Single Agent and In Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
Shivaani Kummar STUDY00022902 Master Protocol: A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations
Shivaani Kummar STUDY00023157 A Phase 1a/b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination with Anticancer Therapies in Subjects with Solid Malignancies
Shivaani Kummar STUDY00023236 A Phase 1 Study of SGN-STNV in Advanced Solid Tumors
Eric Roeland STUDY00023857 A double-blind, placebo-controlled, randomized, dose-escalating, multicenter, Phase 1 study to assess the safety and tolerability of ART-123 in combination with leucovorin/5-fluorouracil/oxaliplatin and bevacizumab in metastatic colorectal cancer patients
 
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080